Streetbeat News

Products Services

CMND

Clearmind Medicine and Yissum have filed an international patent application for new psychedelic compounds aimed at treating PTSD, addressing significant unmet medical needs.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 12:21 pm

PLUG

Plug Power Inc. has signed a contract with Dourogás and CapWatt to provide technical evaluation for 25 MW of its PEM Electrolyzers for a green methanol project in Portugal.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 12:18 pm

ALB

CATL's suspension of lithium carbonate production in Yichun is expected to reduce China's monthly output by 8%, causing a surge in lithium prices. This has led to a short squeeze, benefiting companies like Albemarle and Pilbara Minerals. Analysts have mixed views on the sustainability of the price rebound.

Portfolio Pulse from Stjepan Kalinic

September 12, 2024 | 12:16 pm

G

Genpact and STADA have renewed their multi-year partnership to enhance STADA's finance operations using Genpact's expertise in data, technology, and AI. This collaboration aims to future-proof STADA's finance organization and provide competitive advantages.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 12:16 pm

OSS

One Stop Systems, Inc. (OSS) has entered into a Cooperative Research and Development Agreement with the U.S. Special Operations Command to develop rugged edge AI/ML compute solutions. This partnership aims to enhance cognitive dominance for the Hyper Enabled Force mission objectives, aligning with OSS's strategy to expand its offerings and establish relationships within the U.S. Department of Defense.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 12:15 pm

OSS

One Stop Systems, Inc. (OSS) has entered into a Cooperative Research and Development Agreement with the U.S. Special Operations Command to develop rugged edge AI/ML compute solutions. This partnership aims to enhance cognitive dominance for the Hyper Enabled Force mission objectives.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 12:15 pm

NKGN

NKGen Biotech shares rose following the announcement of early interim data from their Phase 1 cohort and the dosing of the first Phase 2 patient in their Phase 1/2a clinical trial of troculeucel.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 12:14 pm

VYNE

VYNE Therapeutics announced positive Phase 1a SAD trial results for VYN202, a BD2-selective BET inhibitor. The drug was well tolerated with no adverse events, showing dose-dependent exposure and pharmacodynamic activity. The MAD trial phase has begun, with results expected in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 12:13 pm

NKGN

NKGen Biotech has announced promising early interim data from its Phase 1/2a clinical trial of Troculeucel for moderate Alzheimer's Disease. Two out of three patients in the Phase 1 cohort showed improved cognitive scores after receiving the highest dose, indicating a potential shift from moderate to mild Alzheimer's Disease.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 12:12 pm

CVRX

CVRx, Inc. has announced new data published in JACC: Heart Failure, showing long-term quality of life benefits of their Barostim device for heart failure patients. The data highlights improvements in MLWHF and EQ-5D measures over 24 months.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 12:12 pm